Evidence map›Paper›PMID 33841438›Full record

ArticleFrontiers in immunology2021

Plasmacytoid Dendritic Cells Depletion and Elevation of IFN-γ Dependent Chemokines CXCL9 and CXCL10 in Children With Multisystem Inflammatory Syndrome.

Francesca Caldarale, Mauro Giacomelli, Emirena Garrafa, Nicola Tamassia, Alessia Morreale, Piercarlo Poli, Silviana Timpano, Giulia Baresi, Fiammetta Zunica, Marco Cattalini and 8 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. The role of dendritic cells in COVID-19 infection.Emerging microbes & infections · 2023
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Francesca CaldaraleDepartment of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Mauro GiacomelliDepartment of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Emirena GarrafaDepartment of Molecular and translational Medicin and Clinical Chemistry Laboratory ASST Spedali Civili, Brescia, Italy.
Nicola TamassiaSection of General Pathology, Department of Medicine, University of Verona, Verona, Italy.
Alessia MorrealeDepartment of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Piercarlo PoliDepartment of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Silviana TimpanoDepartment of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Giulia BaresiDepartment of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Fiammetta ZunicaDepartment of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Marco CattaliniDepartment of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Daniele MorattoFlow Cytometry & Clinical Chemistry Laboratory, ASST Spedali Civili, Brescia, Italy.
Marco ChiariniFlow Cytometry & Clinical Chemistry Laboratory, ASST Spedali Civili, Brescia, Italy.
Elvira Stefania CannizzoClinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy.
Giulia MarchettiClinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy.
Marco Antonio CassatellaSection of General Pathology, Department of Medicine, University of Verona, Verona, Italy.
Andrea TaddioPediatric Department, IRCCS Burlo Garofolo, Trieste, Italy.
Alberto TommasiniPediatric Department, IRCCS Burlo Garofolo, Trieste, Italy.
Raffaele BadolatoDepartment of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
University of Brescia · ITAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITIRCCS Materno Infantile Burlo Garofolo · ITOspedale San Paolo · ITUniversity of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: SARS-CoV-2 occurs in the majority of children as COVID-19, without symptoms or with a paucisymptomatic respiratory syndrome, but a small proportion of children develop the systemic Multi Inflammatory Syndrome (MIS-C), characterized by persistent fever and systemic hyperinflammation, with some clinical features resembling Kawasaki Disease (KD). Objective: With this study we aimed to shed new light on the pathogenesis of these two SARS-CoV-2-related clinical manifestations. Methods: We investigated lymphocyte and dendritic cells subsets, chemokine/cytokine profiles and evaluated the neutrophil activity mediators, myeloperoxidase (MPO), and reactive oxygen species (ROS), in 10 children with COVID-19 and 9 with MIS-C at the time of hospital admission. Results: Patients with MIS-C showed higher plasma levels of C reactive protein (CRP), MPO, IL-6, and of the pro-inflammatory chemokines CXCL8 and CCL2 than COVID-19 children. In addition, they displayed higher levels of the chemokines CXCL9 and CXCL10, mainly induced by IFN-γ. By contrast, we detected IFN-α in plasma of children with COVID-19, but not in patients with MIS-C. This observation was consistent with the increase of ISG15 and IFIT1 mRNAs in cells of COVID-19 patients, while ISG15 and IFIT1 mRNA were detected in MIS-C at levels comparable to healthy controls. Moreover, quantification of the number of plasmacytoid dendritic cells (pDCs), which constitute the main source of IFN-α, showed profound depletion of this subset in MIS-C, but not in COVID-19. Conclusions: Our results show a pattern of immune response which is suggestive of type I interferon activation in COVID-19 children, probably related to a recent interaction with the virus, while in MIS-C the immune response is characterized by elevation of the inflammatory cytokines/chemokines IL-6, CCL2, and CXCL8 and of the chemokines CXCL9 and CXL10, which are markers of an active Th1 type immune response. We believe that these immunological events, together with neutrophil activation, might be crucial in inducing the multisystem and cardiovascular damage observed in MIS-C.

Indexed as

Chemokine CXCL10Chemokine CXCL9ChildChild, PreschoolCOVID-19Dendritic CellsFemaleHumansInfantInterferon-gammaMalePlasma CellsRetrospective StudiesSARS-CoV-2Systemic Inflammatory Response SyndromeChemokine CXCL10Chemokine CXCL9CXCL10 protein, humanCXCL9 protein, humanIFNG protein, humanInterferon-gammaCOVID-19CXCL10CXCL9IFNmultisystem inflammatory syndrome in childrenneutrophil activationplasmacytoid DCs

Identifiers

PMID33841438
PMCPMC8033149
OpenAlexW3140768927

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.